Collagen type I alpha 2 chain mRNA (COL1A2 mRNA)

COL1A2 mRNA is the transcript of the COL1A2 gene, which encodes the pro-alpha2(I) chain of type I collagen, the primary structural component of the extracellular matrix in bone, skin, and tendons (NIH, 2013). Type I collagen typically exists as a heterotrimer of two alpha1 chains and one alpha2 chain; however, mutations or expression imbalances can lead to the formation of dysfunctional collagen or pathological fibrosis (Liverpool University, 2024). In diseases such as Osteogenesis Imperfecta and Ehlers-Danlos Syndrome, mutations in COL1A2 mRNA result in structural defects, while its overexpression is a key driver of fibrosis in the liver, lungs, and heart (NIH, 2008; ResearchGate, 2025). Furthermore, high levels of COL1A2 mRNA are linked to poor prognosis and chemoresistance in several cancers, including gastric and breast cancer (Frontiers, 2024; Aging-US, 2024). Therapeutic interventions targeting COL1A2 mRNA, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), aim to reduce collagen overproduction or selectively silence mutant alleles (NIH, 2013; Biochemistry, 1994). These RNA-targeted therapies, along with microRNA mimics like Remlarsen, represent a precision medicine approach to treating both rare genetic connective tissue disorders and common fibrotic conditions (Drug Discovery News, 2025).

Other names

Pro-alpha2(I) collagen mRNACollagen alpha-2(I) chain mRNACOL1A2 transcriptType I collagen alpha 2 mRNA

RNA interference (siRNA), antisense inhibition (ASO), and microRNA-mediated regulation leading to mRNA degradation or translational repression.